Julphar Gulf Pharmaceutical Industries is the largest generic pharmaceutical manufacturer in Middle East and North Africa and distributes medicines to over 40 countries. Established in 1980 in the United Arab Emirates under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi, Julphar's first stand-alone facility produced only five products. Over three decades later, we operate fifteen internationally certified manufacturing facilities globally, produce over a million boxes of medicines daily and hold 3,957 product registration certificates.
Thirteen of our facilities are based in the UAE and cover production areas including tablets, syrups and suspensions. Julphar has also launched manufacturing facilities in Ethiopia and in Bangladesh as part of its ongoing international expansion strategy, and its Saudi Arabia facility is expected to begin its operations in 2017.
In 2012 Julphar launched a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility – Julphar Diabetes – entirely dedicated to producing raw material needed for insulin formulation. Julphar Diabetes has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA), equivalent to 40 million vials of insulin per year. This positions Julphar among the largest manufacturers of insulin in the world, and the only one of its kind in the Middle East.
Julphar maintains a diverse product portfolio which targets major therapeutic segments. It includes the following categories: Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care.
As part of its on-going responsibility, Julphar partners with local and global companies to make a positive impact across all healthcare sectors by dedicating 2.5% of its annual profits to Corporate Social Responsibility (CSR). This goes towards funding of scholarships for educational facilities and sponsorship of various health campaigns across MENA.
Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending 2015, demonstrating a significant growth based on last year's results. Emerging markets remain a key priority for sustainable growth, as Julphar’s Middle Eastern roots allow us to reach difficult markets in a timely manner.
With 204 registered products sold in over 40 countries, Julphar is a stellar example of one of the UAE’s local businesses making an impact on the global stage.
Julphar is Current Good Manufacturing Practice (cGMP) compliant and has gained ISO9001 and ISO 14001 accreditations, as well as the EU Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications. We work closely with regulatory bodies, such as the UAE Ministry of Health (MOH) and the US Food and Drug Administration (FDA) to ensure all our practices are aligned with the international requirements.
Julphar in essence is Sustaining Health across the globe.